World Health Organization Sounds Alert Over Acute Lack of Obesity Jabs

Less than a tenth of individuals eligible to benefit from obesity jabs like Wegovy have access to them, warns the World Health Organization as it issues its inaugural recommendations on the therapies.

Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging broader and more equitable availability to this class of drugs.

Per projections, over two billion could be living with obesity by 2030 without intervention.

"Our new guidelines acknowledges that excess weight is a long-term condition that can be addressed with thorough and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and supply-chain constraints are significant barriers to universal access to the jabs that can help people shift considerable body mass, says the agency.

GLP-1 Therapy Supply Crisis

Even under the present most optimistic case, the supply of GLP-1 therapies could only cover around 100 million people – fewer than 10% of those who need them, according to the WHO.

The advice urges countries and companies to expand access, by measures including patent sharing.

A patent on the active ingredient – the core component of a leading brand – is set to lapse in several countries in 2026.

The Way Weight-Loss Injections Operate

The injections replicate a biological compound to reduce digestion speed, curb appetite and increase feelings of fullness so individuals reduce food intake.

Patients usually see weight reduction within a few weeks of starting on the once-weekly jabs.

Research suggests people may regain a significant portion a year later of stopping the drug, when their typical appetite come back.

To be overweight or obese raises your risk for developing medical conditions, like diabetes, cardiovascular issues, stroke, and some malignancies.

Excess weight concerns individuals in all nations and was associated with millions of deaths worldwide in 2024, as per the WHO.